Nykode Therapeutics ASA

Nykode Therapeutics ASA is an Oslo-based clinical-stage biopharmaceutical platform company founded in 2006, dedicated to discovering and developing novel vaccines and immunotherapies for cancer, autoimmune diseases, and infectious diseases. The company leverages its proprietary Vaccibody™ technology, which targets antigens to antigen-presenting cells to induce rapid, strong, and long-lasting immune responses, addressing high unmet medical needs. Key product candidates include VB10.16, a therapeutic cancer vaccine in Phase II trials for HPV16-positive cancers such as cervical cancer, and VB10.NEO, an individualized neoantigen immunotherapy in Phase 1b for advanced tumors. Nykode also advances programs like abi-suva and a tolerance platform, with collaborations alongside Roche, Regeneron, Genentech, MSD, and others enhancing its oncology and infectious disease efforts. Headquartered in Oslo Science Park with around 135 employees, Nykode Therapeutics plays a significant role in biotechnology by pioneering modular immunotherapy solutions rooted in University of Oslo research.